• Therapies
  • Nearly all published randomized trials of incretin therapies have compared them with a placebo or a reference glucose-lowering agent, wrote André J. Scheen, MD, and Régis P. Radermecker, MD, both of the University of Liège in Belgium. (medpagetoday.com)
  • In the point narrative below, Dr. Butler and colleagues provide their opinion and review of the data to date and that we need to reconsider the use of incretin-based therapies because of the growing concern of potential risk and based on a clearer understanding of the mechanism of action. (diabetesjournals.org)
  • In the counterpoint narrative following the contribution by Dr. Butler and colleagues, Dr. Nauck provides a defense of incretin-based therapies and that the benefits clearly outweigh any concern of risk. (diabetesjournals.org)